Tyra Biosciences (TYRA) Net Cash Flow (2020 - 2026)

Tyra Biosciences has reported Net Cash Flow for 7 years, with the latest figure at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 13.56% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at -$15.8 million (up 89.74% YoY), and the FY2025 full-year result was -$14.6 million, down 142.93% from the prior year.
• Net Cash Flow for Q1 2026 stood at $7.6 million, down from $15.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $196.4 million in Q1 2024, with the low at -$157.6 million in Q4 2023.
• Historically, Net Cash Flow has averaged -$12.7 million across 5 years, with a median of -$9.5 million in 2023.
• The largest YoY upside for Net Cash Flow was 2164.34% in 2024 against a maximum downside of 1567.48% in 2024.
• Tyra Biosciences' Net Cash Flow stood at -$12.0 million in 2022, then plunged by 1213.94% to -$157.6 million in 2023, then surged by 92.43% to -$11.9 million in 2024, then surged by 229.43% to $15.4 million in 2025, then plunged by 50.97% to $7.6 million in 2026.
• The last three Net Cash Flow figures came in at $7.6 million (Q1 2026), $15.4 million (Q4 2025), and -$36.5 million (Q3 2025), per Business Quant data.